{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T06:28:41Z","timestamp":1789972121948,"version":"4.0.1"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2015,6,13]],"date-time":"2015-06-13T00:00:00Z","timestamp":1434153600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Calcif Tissue Int"],"published-print":{"date-parts":[[2015,8]]},"DOI":"10.1007\/s00223-015-0021-6","type":"journal-article","created":{"date-parts":[[2015,6,12]],"date-time":"2015-06-12T07:35:22Z","timestamp":1434094522000},"page":"101-103","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Bisphosphonate Treatment of Children and Adults with Osteogenesis Imperfecta: Unanswered Questions"],"prefix":"10.1007","volume":"97","author":[{"given":"Evelise","family":"Brizola","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay Robert","family":"Shapiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,6,13]]},"reference":[{"key":"21_CR1","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1007\/BF00350961","volume":"16","author":"JP Devogelaer","year":"1987","unstructured":"Devogelaer JP, Malghem J, Maldague B, Nagant de Deuxehaisnes C (1987) Radiological manifestations of bisphosphonate treatment with APD in a child suffering from osteogenesis imperfecta. Skeletal Radiol 16:360\u2013363","journal-title":"Skeletal Radiol"},{"issue":"14","key":"21_CR2","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJM199810013391402","volume":"339","author":"FH Glorieux","year":"1998","unstructured":"Glorieux FH, Bishop NJ, Plotkin H, Chabot G, Lanoue G, Travers R (1998) Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med 339(14):947\u2013952","journal-title":"N Engl J Med"},{"issue":"2","key":"21_CR3","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s00223-001-1055-5","volume":"72","author":"JR Shapiro","year":"2003","unstructured":"Shapiro JR, McCarthy EF, Rossiter K, Ernest K, Gelman R, Fedarko N, Santiago HT, Bober M (2003) The effect of intravenous pamidronate on bone mineral density, bone histomorphometry, and parameters of bone turnover in adults with type IA osteogenesis imperfecta. Calcif Tissue Int 72(2):103\u2013112","journal-title":"Calcif Tissue Int"},{"issue":"2","key":"21_CR4","first-page":"989","volume":"13","author":"FH Glorieux","year":"2000","unstructured":"Glorieux FH (2000) Bisphosphonate therapy for severe osteogenesis imperfecta. J Pediatr Endocrinol Metab 13(2):989\u2013992","journal-title":"J Pediatr Endocrinol Metab"},{"issue":"6","key":"21_CR5","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1097\/MOP.0b013e328332c68f","volume":"21","author":"JR Shapiro","year":"2009","unstructured":"Shapiro JR, Sponsellor PD (2009) Osteogenesis imperfecta: questions and answers. Curr Opin Pediatr 21(6):709\u2013716. doi: 10.1097\/MOP.0b013e328332c68f","journal-title":"Curr Opin Pediatr"},{"issue":"5","key":"21_CR6","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/nrendo.2009.58","volume":"5","author":"JC Marini","year":"2009","unstructured":"Marini JC (2009) Bone: use of bisphosphonates in children-proceed with caution. Nat Rev Endocrinol 5(5):241\u2013243. doi: 10.1038\/nrendo.2009.58","journal-title":"Nat Rev Endocrinol"},{"key":"21_CR7","first-page":"CD005088","volume":"4","author":"CA Phillipi","year":"2008","unstructured":"Phillipi CA, Remmington T, Steiner RD (2008) Bisphosphonate therapy for osteogenesis imperfecta. Cochrane Database Syst Rev 4:CD005088. doi: 10.1002\/14651858.CD005088.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"21_CR8","first-page":"CD005088","volume":"7","author":"K Dwan","year":"2014","unstructured":"Dwan K, Phillipi CA, Steiner RD, Basel D (2014) Bisphosphonate therapy for osteogenesis imperfecta. Cochrane Database Syst Rev 7:CD005088. doi: 10.1002\/14651858.CD005088.pub3","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"21_CR9","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1002\/jbmr.2410","volume":"30","author":"JD Hald","year":"2015","unstructured":"Hald JD, Evangelou E, Langdahl BL, Ralston SH (2015) Bisphosphonates for the prevention of fractures in osteogenesis imperfecta: meta-analysis of placebo-controlled trials. J Bone Miner Res 30(5):929\u2013933. doi: 10.1002\/jbmr.2410","journal-title":"J Bone Miner Res"},{"key":"21_CR10","doi-asserted-by":"crossref","unstructured":"Shi CG, Zhang Y, Yuan W (2015) Efficacy of bisphosphonates on bone mineral density and fracture rate in patients with osteogenesis imperfecta: a systematic review and meta-analysis. Am J Ther. doi: 10.1097\/MJT.0000000000000236","DOI":"10.1097\/MJT.0000000000000236"},{"issue":"1","key":"21_CR11","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s00198-011-1658-2","volume":"23","author":"LA Bradbury","year":"2012","unstructured":"Bradbury LA, Barlow S, Geoghegan F, Hannon RA, Stuckey SL, Wass JA, Russell RG, Brown MA, Duncan EL (2012) Risedronate in adults with osteogenesis imperfecta type I: increased bone mineral density and decreased bone turnover, but high fracture rate persists. Osteoporos Int 23(1):285\u2013294","journal-title":"Osteoporos Int"},{"issue":"9","key":"21_CR12","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1172\/JCI0215952","volume":"110","author":"F Rauch","year":"2002","unstructured":"Rauch F, Travers R, Plotkin H, Glorieux FH (2002) The effects of intravenous pamidronate on the bone tissue of children and adolescents with osteogenesis imperfecta. J Clin Invest 110(9):1293\u20131299","journal-title":"J Clin Invest"},{"issue":"3","key":"21_CR13","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.bone.2006.02.071","volume":"39","author":"M Weber","year":"2006","unstructured":"Weber M, Roschger P, Fratzl-Zelman N, Sch\u00f6berl T, Rauch F, Glorieux FH, Fratzl P, Klaushofer K (2006) Pamidronate does not adversely affect bone intrinsic material properties in children with osteogenesis imperfecta. Bone 39(3):616\u2013622","journal-title":"Bone"},{"issue":"2","key":"21_CR14","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1210\/jc.2008-1531","volume":"94","author":"LK Bachrach","year":"2009","unstructured":"Bachrach LK, Ward LM (2009) Clinical review: bisphosphonate use in childhood osteoporosis. J Clin Endocrinol Metab 94(2):400\u2013409. doi: 10.1210\/jc.2008-1531","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"21_CR15","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1210\/jc.2005-2036","volume":"91","author":"F Rauch","year":"2006","unstructured":"Rauch F, Travers R, Glorieux FH (2006) Pamidronate in children with osteogenesis imperfecta: histomorphometric effects of long-term therapy. J Clin Endocrinol Metab 91(2):511\u2013516","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"21_CR16","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1210\/en.2013-1993","volume":"155","author":"ED Zhu","year":"2014","unstructured":"Zhu ED, Louis L, Brooks DJ, Bouxsein ML, Demay MB (2014) Effect of bisphosphonates on the rapidly growing male murine skeleton. Endocrinology 155(4):1188\u20131196. doi: 10.1210\/en.2013-1993","journal-title":"Endocrinology"},{"issue":"4","key":"21_CR17","doi-asserted-by":"crossref","first-page":"345","DOI":"10.59566\/IJBS.2009.5345","volume":"5","author":"KD Evans","year":"2009","unstructured":"Evans KD, Sheppard LE, Rao SH, Martin RB, Oberbauer AM (2009) Pamidronate alters the growth plate in the oim mouse model for osteogenesis imperfecta. Int J Biomed Sci 5(4):345\u2013352","journal-title":"Int J Biomed Sci"},{"key":"21_CR18","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1007\/s00247-011-2198-9","volume":"42","author":"TH Harcke","year":"2012","unstructured":"Harcke TH, Stevenson KL, Kecskemethy HH, Bachrach SJ, Grisso LE (2012) Fracture after bisphosphonate treatment in children with cerebral palsy: the role of stress risers. Pediatr Radiol 42:76\u201381. doi: 10.1007\/s00247-011-2198-9","journal-title":"Pediatr Radiol"},{"key":"21_CR19","unstructured":"Hegazy A, Howard A, Sochett E, Tile L, Cheung AM (2012) Femur stress fractures in children with osteogenesis imperfecta and intramedullary rods on long-term intravenous pamidronate therapy. J Bone Miner Res 27(1). http:\/\/www.asbmr.org\/Meetings\/AnnualMeeting\/Abstracts12.aspx . Acessed 12 April 2015"}],"container-title":["Calcified Tissue International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00223-015-0021-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00223-015-0021-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00223-015-0021-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,9]],"date-time":"2024-06-09T13:28:33Z","timestamp":1717939713000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00223-015-0021-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6,13]]},"references-count":19,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,8]]}},"alternative-id":["21"],"URL":"https:\/\/doi.org\/10.1007\/s00223-015-0021-6","relation":{},"ISSN":["0171-967X","1432-0827"],"issn-type":[{"value":"0171-967X","type":"print"},{"value":"1432-0827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,6,13]]}}}